What's atypical about atypical antipsychotic drugs?

被引:119
作者
Meltzer, HY [1 ]
机构
[1] Vanderbilt Univ, Hosp Psychiat, Nashville, TN 37212 USA
关键词
D O I
10.1016/j.coph.2003.09.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Atypical antipsychotic drugs, by definition, differ from typical antipsychotic agents in producing significantly fewer extrapyramidal symptoms and having a lower risk of tardive dyskinesia in vulnerable clinical populations at doses that produce comparable control of psychosis. The atypical drugs differ from the typicals in their mechanism of action, but not all share the same mechanism. Many, but not all, atypicals have been found to improve cognitive function, which could be their most important advantage with regard to efficacy. Clozapine, the prototype of these agents, has been found to improve delusions and hallucinations in patients who fail to respond to other antipsychotic drugs, and to reduce the risk of suicide. These agents have been found to increase cortical dopamine and acetylcholine release, as well as have a variety of effects on the glutamatergic system not shared by the typical agents. Effects on neuronal survival and plasticity, together with decreased neurotoxicity, might also contribute to their clinical advantage over typical neuroleptic drugs.
引用
收藏
页码:53 / 57
页数:5
相关论文
共 41 条
[1]   Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs [J].
Andersson, C ;
Hamer, RM ;
Lawler, CP ;
Mailman, RB ;
Lieberman, JA .
NEUROPSYCHOPHARMACOLOGY, 2002, 27 (02) :143-151
[2]   Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs [J].
Bai, O ;
Chlan-Fourney, J ;
Bowen, R ;
Keegan, D ;
Li, XM .
JOURNAL OF NEUROSCIENCE RESEARCH, 2003, 71 (01) :127-131
[3]   Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives [J].
Baptista, T ;
Kin, NMKNY ;
Beaulieu, S ;
de Baptista, EA .
PHARMACOPSYCHIATRY, 2002, 35 (06) :205-219
[4]   Optimizing limbic selective D2/D3 receptor occupancy by risperidone:: A[123I]-epidepride SPET study [J].
Bressan, RA ;
Erlandsson, K ;
Jones, HM ;
Mulligan, RS ;
Ell, PJ ;
Pilowsky, LS .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (01) :5-14
[5]   Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors [J].
Burris, KD ;
Molski, TF ;
Xu, C ;
Ryan, E ;
Tottori, K ;
Kikuchi, T ;
Yocca, FD ;
Molinoff, PB .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :381-389
[6]   Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol [J].
Cochran, SM ;
McKerchar, CE ;
Morris, BJ ;
Pratt, JA .
NEUROPHARMACOLOGY, 2002, 43 (03) :394-407
[7]   DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS [J].
CREESE, I ;
BURT, DR ;
SNYDER, SH .
SCIENCE, 1976, 192 (4238) :481-483
[8]  
D'Souza C, 2003, INT J CLIN PRACT, V57, P295
[9]   A meta-analysis of the efficacy of second-generation antipsychotics [J].
Davis, JM ;
Chen, N ;
Glick, ID .
ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (06) :553-564
[10]   Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation [J].
Duncan, GE ;
Miyamoto, S ;
Lieberman, JA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (03) :999-1005